NICE rejects Imnovid for Multiple Myeloma in final guidance-Celgene
The National Institute for Health and Care Excellence has given final guidance rejecting Imnovid (pomalidomide), from Celgene, for treating multiple myeloma after third or subsequent relapse, because analyses from Celgene “showed that it does not offer enough benefit to justify its high price”.
Comment: Pomalyst/Imnovid is in a crowded market. Takeda plans to file ixazomib, an oral protease inhibitor, and follow on to Velcade ( US patent expires 2017). The filing will be based on the TOURAMALINE - MMI trial. In contrast to Velcade and Kyprolis, ixazomib is an oral drug and possibly has fewer side effects than Velcade, such as peripheral neuropathy.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.